Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 May 17;20(1):1095-1097.
doi: 10.1007/s40200-021-00819-x. eCollection 2021 Jun.

Targeting TMAO and its metabolic pathway for cardiovascular diseases treatment

Zahra Hoseini-Tavassol  1 , Shirin Hasani-Ranjbar  1
Affiliations
Editorial

Targeting TMAO and its metabolic pathway for cardiovascular diseases treatment

Zahra Hoseini-Tavassol et al. J Diabetes Metab Disord. .

Abstract

Given the prevalence of cardiovascular diseases (CVDs), as one of the most important non-communicable diseases (NCDs), the recognition of diagnostic biomarkers and potential treatment methods is very crucial. Today gut microbiota composition and its derived metabolites modification are known as one of the recent therapeutic strategies. Studies show that Trimethylamine N-oxide (TMAO) is a gut microbiota-derived metabolite that may be involved in the development of cardiovascular diseases, including ischemic disease and atherosclerosis, atrial fibrillation and arrhythmia, and heart failure. Due to existing some disagreements in this manner, future studies are needed to obtain a definitive sight of the association between this metabolite and CVDs. TMAO may be beneficial as a prognostic marker, which represents the degree of gut microbiota dysbiosis and subsequently CVD events and also different therapies methods based on TMAO and its metabolic pathways can be the target of clinical trial on cardiovascular disease and/or its prevention.

Keywords: Biomarkers; Cardiovascular disease; Gut Microbiota; Therapeutics; Trimethylamine N-oxide (TMAO).

PubMed Disclaimer

Conflict of interest statement

Conflict of interestsThe authors declare that they have no conflict interests.

Similar articles

See all similar articles

Cited by

References

    1. Heianza Y, Ma W, Manson JE, Rexrode KM, Qi L. Gut microbiota metabolites and risk of major adverse cardiovascular disease events and death: a systematic review and meta-analysis of prospective studies. J Am Heart Assoc. 2017;6(7):e004947. doi: 10.1161/JAHA.116.004947. - DOI - PMC - PubMed
    1. Ejtahed HS, Angoorani P, Soroush AR, Hasani-Ranjbar S, Siadat SD, Larijani B. Gut microbiota-derived metabolites in obesity: a systematic review. Biosci Microbiota Food Health. 2020;39(3):65–76. - PMC - PubMed
    1. Janeiro MH, Ramírez MJ, Milagro FI, Martínez JA, Solas M. Implication of trimethylamine N-oxide (TMAO) in disease: potential biomarker or new therapeutic target. Nutrients. 2018;10(10):1398. doi: 10.3390/nu10101398. - DOI - PMC - PubMed
    1. Zhang Y, Wang Y, Ke B, Du J. TMAO: how gut microbiota contributes to heart failure. Translational Research: The Journal of Laboratory and Clinical Medicine. 2021;228:109–25. - PubMed
    1. Guasti L, Galliazzo S, Molaro M, Visconti E, Pennella B, Gaudio GV, et al. TMAO as a biomarker of cardiovascular events: a systematic review and meta-analysis. Intern Emerg Med. 2021;16(1):201–7. - PubMed

Publication types

LinkOut - more resources